Compass Therapeutics Inc (CMPX)

Health Services • Health Care

Stock AI

News & Reports

July 17, 2026 Compass Therapeutics Announces Exciting Data Presentation at ESMO Congress 2026 Compass Therapeutics will present pivotal trial data on tovecimig for advanced biliary tract cancer at ESMO 2026. This presentation highlights their commitment to innovative cancer therapies.

May 28, 2026 Compass Therapeutics to Showcase Innovations at June Investor Events Compass Therapeutics will participate in two major investor events in June 2026, showcasing its advancements in antibody-based therapeutics for oncology. The company aims to engage with investors and highlight its strategic vision during these significant gatherings.

May 21, 2026 Compass Therapeutics Unveils Promising Phase 1 Clinical Data at ASCO 2026 Compass Therapeutics has unveiled encouraging Phase 1 clinical data for CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, ahead of ASCO 2026. Key findings include a 33% overall response rate and impressive durability in patients with advanced malignancies. The company plans to expand cohorts based on these results.

May 05, 2026 Compass Therapeutics Reports Q1 2026 Financial Results and Corporate Developments Compass Therapeutics announced its Q1 2026 financial results, showcasing significant progress in clinical trials, particularly for tovecimig in biliary tract cancer. The company is also advancing other oncology candidates while maintaining a strong cash position for future developments.

May 05, 2026 Compass Therapeutics Inc. Releases Q1 2026 Financial Results: A Look at Progress and Challenges Compass Therapeutics reported significant advancements in Q1 2026, including positive Phase 2/3 results for its lead candidate, tovecimig. Despite an increase in net losses, the company showed a strong cash position and received FDA Orphan Drug Designation, positioning it well for future growth in oncology.

April 27, 2026 Compass Therapeutics Inc. Reports Compelling Results for Tovecimig in Biliary Tract Cancer Study Compass Therapeutics, Inc. announced successful results from the COMPANION-002 trial, demonstrating significant improvements in progression-free survival for biliary tract cancer patients treated with tovecimig. The study highlights a 56% reduction in disease progression risk and a notable overall response rate, marking a potential breakthrough in oncology treatment.

April 24, 2026 Compass Therapeutics Announces Upcoming Webcast on Phase 2/3 Study Results for Tovecimig in Biliary Tract Cancer Compass Therapeutics will host a webcast on April 27, 2026, to discuss results from its Phase 2/3 study on tovecimig for biliary tract cancer. The event aims to provide critical insights into this innovative treatment approach.

March 05, 2026 Compass Therapeutics Inc. Reports 2025 Financial Results and Corporate Update Compass Therapeutics Inc. reports a net loss of $66.5 million for 2025, highlighting advancements in their oncology pipeline, particularly with tovecimig. The company anticipates pivotal clinical data in 2026 and a strengthened leadership team to drive future growth.

March 05, 2026 Compass Therapeutics Inc. Reports Financial Results for 2025: A Year of Growth and Strategic Funding Compass Therapeutics Inc. reported a net loss of $66.48 million for 2025, with increased R&D investments of $55.96 million. The company is focused on advancing its oncology pipeline while exploring further funding to support its growth.

January 06, 2026 Compass Therapeutics Provides Corporate Update for 2026 Compass Therapeutics has provided a corporate update for 2026, highlighting key advancements in its oncology pipeline, including the promising drug tovecimig. With a strong financial base, the company aims to navigate clinical challenges and expand its therapeutic impact across various cancer types.

January 05, 2026 Compass Therapeutics Announces Significant Inducement Grants for New Executives Compass Therapeutics granted 2 million stock options to newly appointed executives Arjun Prasad and Cynthia Sirard to attract top talent. This strategic move supports the company's innovation in oncology therapeutics as they advance their promising pipeline.

January 05, 2026 Compass Therapeutics Announces Key Leadership Appointments Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Dr. Cynthia Sirard as Chief Medical Officer, both effective January 1, 2026. Their extensive experience is expected to drive the company's oncology initiatives, particularly the development of the therapeutic tovecimig.

December 17, 2025 Compass Therapeutics Set to Shine at J.P. Morgan 2026 Healthcare Conference Compass Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, highlighting its antibody-based oncology therapies. The company will also host investor meetings to foster relationships and discuss its promising therapeutic pipeline.

November 25, 2025 Compass Therapeutics Announces Participation in December Investor Events Compass Therapeutics will attend key investor events in December 2025, including the Piper Sandler and Evercore Healthcare Conferences. These sessions will offer insights into the company's oncology therapeutics and provide opportunities for one-on-one meetings with management, enhancing investor relations.

November 05, 2025 Compass Therapeutics Reports Strong Q3 2025 Financial Results Amid Promising Clinical Developments Compass Therapeutics announced its Q3 2025 financial results, showcasing strong progress in its clinical pipeline, particularly with tovecimig and CTX-8371. The company is well-positioned for future growth in oncology therapeutics, backed by a solid cash position and investor confidence.

November 05, 2025 Compass Therapeutics Inc. Reports 2025 Q3 Financial Results: Navigating Through Challenges Compass Therapeutics reported its Q3 2025 financial results, showcasing significant operational losses amid advancements in its drug pipeline. The company focuses on innovative oncology therapies, with promising candidates in clinical trials and a robust outlook despite funding challenges.

November 04, 2025 Compass Therapeutics Presents Promising Preclinical Data on CTX-10726 at SITC Annual Meeting Compass Therapeutics presented groundbreaking preclinical data on CTX-10726 at the SITC Annual Meeting, highlighting its significant efficacy against cancer. The bispecific antibody targets PD-1 and VEGF-A, showing robust in vitro and in vivo anti-tumor activity, paving the way for enhanced cancer therapies.

November 03, 2025 Compass Therapeutics Announces Participation in November Investor Events Compass Therapeutics is set to participate in major investor events this November, including conferences in Boston, New York, and London. These gatherings will highlight the company's advancements in antibody-based oncology therapeutics and foster investor engagement.

August 11, 2025 Compass Therapeutics Inc. Reports Q2 2025 Financial Results: A Mixed Bag of Progress and Challenges Compass Therapeutics Inc. reported its Q2 2025 financial results, showing increased losses despite advancements in clinical trials, particularly for tovecimig. The company faces significant funding challenges while planning for future growth in the oncology sector.

May 08, 2025 Compass Therapeutics Inc. Reports Q1 2025 Financial Results: Key Developments and Financial Performance Compass Therapeutics Inc. reports a net loss of $16.6 million in Q1 2025, despite promising clinical results for its lead candidate, tovecimig. The company anticipates the need for significant additional funding to support ongoing operations and product development.

April 02, 2025 Compass Therapeutics Set to Showcase Innovations at Stifel 2025 Virtual Targeted Oncology Forum Compass Therapeutics will present at the Stifel 2025 Virtual Targeted Oncology Forum on April 8, showcasing its innovative antibody-based cancer therapies. The company focuses on angiogenesis, immune response activators, and overcoming immunosuppression for effective cancer treatment.

April 01, 2025 Compass Therapeutics Unveils Promising Data for Tovecimig in Biliary Tract Cancer Compass Therapeutics revealed groundbreaking results from their COMPANION-002 trial for tovecimig in biliary tract cancer, achieving a 17.1% overall response rate. This combination therapy shows potential as a new treatment option for patients with limited alternatives.

March 31, 2025 Compass Therapeutics Set to Unveil Promising Clinical Data for Tovecimig in Biliary Tract Cancer Compass Therapeutics is set to present crucial clinical data from the COMPANION-002 trial on April 1, 2025. The trial evaluates the efficacy of tovecimig, a bispecific antibody, in conjunction with paclitaxel for advanced biliary tract cancer. This webcast aims to provide insights that could impact treatment approaches for this challenging condition.

February 27, 2025 Compass Therapeutics Reports 2024 Financial Results and Corporate Update Compass Therapeutics reports a net loss of $49.4 million for 2024, driven by increased R&D spending. The company highlights key advances in its oncology pipeline, including the COMPANION-002 trial for tovecimig, with data expected in March 2025.

February 27, 2025 Compass Therapeutics Inc. Reports 2024 Annual Results: A Year of Growth Amidst Challenges Compass Therapeutics Inc. released its 2024 annual report, reporting $850K in revenue but a net loss of $49.4M. The company remains focused on advancing its innovative pipeline amidst financial challenges.

January 27, 2025 SWOT Analysis of Compass Therapeutics Inc in 2025 This SWOT analysis examines Compass Therapeutics Inc, highlighting its strengths in innovative oncology therapies and challenges related to its operating history and funding. The company faces intense competition but has opportunities for growth through partnerships and advancements in personalized medicine.

November 12, 2024 Compass Therapeutics Inc. Reports Q3 2024 Financial Results: A Steady Focus Amid Challenges Compass Therapeutics has released its Q3 2024 financial results, showing a net loss of $10.48 million. While facing challenges in clinical trials, the company is set to initiate a new trial for CTX-009 in mid-2025, underscoring its commitment to oncology innovation.

August 12, 2024 Compass Therapeutics Inc. Reports Q2 2024 Financial Results: Progress Amid Challenges Compass Therapeutics reported its Q2 2024 financial results, emphasizing progress in clinical trials for CTX-009 and CTX-471. Despite a $23.9 million net loss, the company maintains a strong cash position and plans for future funding strategies to support its oncology innovations.

May 13, 2024 Compass Therapeutics Inc. Reports Q1 2024 Financial Results: A Look at Performance & Future Prospects Compass Therapeutics Inc. reported a net loss of $10.8 million for Q1 2024, driven by increased operational costs. Despite financial challenges, the company continues to advance its promising product pipeline, including CTX-009 and CTX-471, while planning for future funding needs.

March 21, 2024 Compass Therapeutics Inc. Reports 2023 Annual Financial Results Compass Therapeutics, Inc. reports a net loss of $42.49 million for 2023, driven by significant R&D investments. Despite challenges, the company remains focused on advancing its cancer therapeutics and expanding operations.

SWOT Analysis of Compass Therapeutics Inc in 2025

Last updated: January 27, 2025

This SWOT analysis provides a comprehensive overview of Compass Therapeutics Inc, a clinical-stage biopharmaceutical company focusing on innovative cancer therapies. The analysis highlights the company's strengths, weaknesses, opportunities, and threats as of 2025, offering insights into its strategic position within the competitive biopharmaceutical landscape.

Strengths

Strong pipeline with innovative product candidates targeting significant unmet medical needs in oncology
Proprietary technologies and patents that provide a competitive edge
Experienced management team with a proven track record in biotechnology and drug development
Focus on the modulation of tumor microenvironments enhances therapeutic effectiveness
Successful navigation of complex regulatory pathways enhances credibility

Weaknesses

Limited operating history and no approved products to date, raising investor concerns
Significant accumulated losses, creating uncertainty around future profitability
Heavy reliance on external funding to support operations and clinical trials
Challenges in patient enrollment and trial execution could delay product development

Opportunities

Growing demand for innovative cancer therapies in a rapidly evolving market
Potential partnerships and collaborations with larger pharmaceutical companies to enhance development capabilities
Expansion of product indications for CTX-009 to capture broader market segments
Advances in immunotherapy and personalized medicine create new avenues for growth
Increasing focus on oncology within regulatory frameworks may facilitate approvals

Threats

Intense competition from established pharmaceutical companies with robust oncology portfolios
Unpredictable outcomes of clinical trials and the potential for regulatory delays
Market acceptance challenges for novel therapies amidst established treatment options
Dependence on third-party manufacturers and clinical trial organizations introduces operational risks
Potential for intellectual property litigation could divert resources and impact operations

Compass Therapeutics Inc stands at a pivotal point in its development as it seeks to advance its innovative therapies in the competitive oncology landscape. While the company possesses strong strengths and significant opportunities, it must navigate critical weaknesses and external threats to achieve long-term success. Continuous strategic focus on product development, regulatory navigation, and market positioning will be essential for sustainable growth.

You may also be interested in: